Market Research Reports

  The Cladribine market is gaining traction globally, driven by its increasing use in treating multiple sclerosis (MS) and certain cancers such as hairy cell leukemia. Cladribine, a synthetic purine nucleoside analogue, disrupts DNA synthesis in rapidly dividing cells, making it an effective treatment for these proliferative conditions. Originally approved for hematologic cancers, Cladribine has now been repurposed as an oral therapy for relapsing forms of MS, offering patients a more convenient alternative to traditional injectable treatments. With rising MS prevalence, growing patient preference for oral medications, and significant advancements in pharmaceutical research, the Cladribine market is positioned for steady growth in the coming years. Get a sample copy of this report:  https://wemarketresearch.com/reports/request-free-sample-pdf/cladribine-market/1490 Cladribine Market  Growth Drivers Rising MS Prevalence : An increase in the number of people diagnosed with...